Last reviewed · How we verify
NCT03938662
S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease
NA trial testing formulation containing S-Adenosyl methionine and choline in Alcoholic Liver Diseases in 44 participants. Status unknown.
1 April 2020
Quick facts
| Lead sponsor | University Clinic Dr Dragisa Misovic-Dedinje |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 9 May 2019 |
| Primary completion | 1 April 2020 |
| Estimated completion | 1 April 2020 |
| Sites | 1 location across Serbia |
Drugs / interventions tested
- formulation containing S-Adenosyl methionine and choline
- Placebo
Conditions studied
- Alcoholic Liver Diseases — all drugs for Alcoholic Liver Diseases →
Sponsor
University Clinic Dr Dragisa Misovic-Dedinje
Who can join
18 and older, any sex, with Alcoholic Liver Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will assess the effect of treatment with formulation containing S-Adenosyl methionine and choline, on patients with alcoholic liver disease. Half of the patients included will receive named formulation once daily for 24 weeks while other half will receive placebo.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Epidemiological Realities of Alcoholic Liver Disease: Global Burden, Research Trends, and Therapeutic Promise.
Xiao J, Wang F, Wong NK, Lv Y, et al · · 2020 · cited 28× · PMID 32690129 · DOI 10.3727/105221620x15952664091823 -
Reactive oxygen species (ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants.
Sharma P, Nandave M, Nandave D, Yadav S, et al · · 2023 · cited 20× · PMID 38074830 -
Emerging Pharmacotherapies in Alcohol-Associated Hepatitis.
Wakil A, Niazi M, Meybodi MA, Pyrsopoulos NT. · · 2023 · cited 10× · PMID 36647403 · DOI 10.1016/j.jceh.2022.06.012 -
Small-molecule chemical probes for the potential therapeutic targets in alcoholic liver diseases.
Dogra A, Li F. · · 2023 · cited 1× · PMID 39958379 · DOI 10.1016/j.livres.2023.09.001
Verify or expand the search:
- PubMed search for NCT03938662
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Clinic Dr Dragisa Misovic-Dedinje trials
Trials by the same sponsor.
- NCT05957744 — Nutritional Risk Factors and Colorectal Surgery · unknown
- NCT05973435 — Evaluation of the Level of Oxidative Stress in Relation to the Type of Anesthesia in Parturients Whose Delivery Was Comp · completed
- NCT03941418 — Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03938662 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Clinic Dr Dragisa Misovic-Dedinje
- Last refreshed: 29 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03938662.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing